In conclusion, this study has revealed that SGLT2 inhibition can increase the risk of obsessive-compulsive disorder, anxiety disorder, and bipolar affective disorder through mechanisms beyond its hypoglycemic effects. This evidence concerns the gene SLC5A2 and anxiety disorder.